What Maxim Thinks Of Cytori After Its Huge Week
In a report published Wednesday, Maxim Group analyst Jason Kolbert discussed Cytori Therapeutics Inc (NASDAQ: CYTX)'s announcement earlier this week that the European Medicines Agency Committee for Orphan Medicinal Products has designed Cytori's ECC S-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma.
Kolbert noted that the regulatory clearance officially makes Cytori's Celution System available in the largest healthcare market in the world and triggers a "substantial" 2015 product purchase order for Cytori from Lorem Vascular Pte. Ltd.
Related Link: Exclusive: Cytori Therapeutics CEO Talks About Two Major Announcements In Two Days
Meanwhile, Cytori is about to begin a phase 3 clinical trial in the U.S. with the same product in up to 20 sites. Kolbert stated that the clinical data could also be used to support regulatory approvals and reimbursement in the European Union as well as other global markets.
Shares remain Buy rated with a $7 price target.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: ECC S-50 European Medicines Agency Committee for Orphan Medicinal Products Jason Kolbert Lorem VascularAnalyst Color Health Care Analyst Ratings General
